Comparable results were obtained in immunocompetent C57BL/6J mice with murine GL261 glioma tumours treated by CED of [177Lu]Lu-MCP-AuNPs (2.7 MBq) combined with anti-programmed cell death-1 (PD1) checkpoint immunotherapy (Georgiou et al. 2024). This evidence concerns the gene PDCD1 and central nervous system cancer.